Increasing antibody affinity by altering glycosylation of immunoglobulin variable region

• US 6,933,368 B2
• Filed: 02/25/2002
• Issued: 08/23/2005
• Est. Priority Date: 03/09/1992
• Status: Expired due to Fees

• Current Assignee: Facet Biotech Corporation
• Original Assignee: Memorial Sloan-Kettering Cancer Center, Protein Design Labs, Inc. (PDL BioPharma, Inc.)
• Inventors: Scheinberg, David A., Co, Man Sung, Queen, Cary L.
• Primary Examiner(s): HELMS, LARRY RONALD
• Application Number:
  US10/084,825
• Publication Number:
  US 20030054497A1
• Time in Patent Office: 1,275 Days
• Field of Search: 435/69.6, 530/387.1, 530/387.3, 530/388.85, 424/130.1
• US Class Current: 530/387.3
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere

Abstract

The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.

Claims

1. A mutant antibody that comprises a mutant immunoglobulin chain, the mutant antibody having higher affinity for an antigen than a parent antibody that comprises a parent immunoglobulin chain, wherein the mutant immunoglobulin chain comprises an amino acid substitution that eliminates a variable region glycosylation site of the parent immunoglobulin chain, said elimination having the effect of increasing the affinity of the mutant antibody relative to the parent antibody.

2. The mutant antibody of claim 1, wherein the glycosylation site is an N-linked glycosylation site selected from the group consisting of:

(1)-Asn-X-Ser-; and

(2)-Asn-X-Thr-;

wherein X is an amino acid other than Pro.

3. The mutant antibody of claim 1, wherein the glycosylation site is an O-linked glycosylation site selected from the group consisting of:

(1)-Thr-X-X-Pro-; and

(2)-Ser-X-X-Pro-;

wherein X is an amino acid.

4. The mutant antibody of claim 1, wherein the mutant antibody is a humanized version of the parent antibody.

5. The mutant antibody of claim 1, whose variable region has no glycosylation sites.

6. The mutant antibody of claim 1, whose variable region has no N-linked glycosylation sites.

7. The mutant antibody of claim 1, wherein the parent antibody is murine M195 antibody.

8. The mutant antibody of claim 1, wherein the mutant antibody is a humanized M195 antibody.

9. The mutant antibody of claim 1, wherein the antigen is a cell surface glycoprotein.

10. The mutant antibody of claim 1, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

11. The mutant antibody of claim 1, wherein the amino acid substitution is a conservative amino acid substitution.

12. The mutant antibody of claim 2, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

13. The mutant antibody of claim 2, wherein the amino acid substitution is a conservative amino acid substitution.

14. The mutant antibody of claim 3, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

15. The mutant antibody of claim 3, wherein the amino acid substitution is a conservative amino acid substitution.

16. The mutant antibody of claim 9, wherein the cell surface glycoprotein is the CD33 antigen.

17. The mutant antibody of claim 1, wherein the mutation is in a complementary determining region of the parent immunoglobulin chain and the parent antibody binds an epitope of the antigen consisting of polypeptide.

18. A method for producing a mutant antibody having higher affinity for an antigen relative to a parent antibody, the method comprising

introducing a mutation into a polynucleotide sequence encoding a chain of the parent antibody, whereby the polynucleotide encodes a mutant immunoglobulin chain comprising an amino acid substitution that eliminates a variable region glycosylation site of the parent immunoglobulin chain,

expressing said mutant sequence in a cell;

and

determining that said elimination has the effect of increasing the affinity of the mutant antibody relative to the parent antibody.

19. The method of claim 18, wherein the amino acid substitution is a conservative amino acid substitution.

20. The method of claim 18, wherein the mutation is in a complementary determining region of the parent immunoglobulin chain and the parent antibody binds an epitope of the antigen consisting of polypeptide.